Winthrop Advisory Group LLC Makes New $221,000 Investment in Amgen Inc. (NASDAQ:AMGN)

Winthrop Advisory Group LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGNFree Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 685 shares of the medical research company’s stock, valued at approximately $221,000.

A number of other large investors also recently bought and sold shares of AMGN. Vista Capital Partners Inc. purchased a new position in Amgen during the third quarter valued at $238,000. Lewis Asset Management LLC lifted its stake in Amgen by 24.1% in the 3rd quarter. Lewis Asset Management LLC now owns 1,498 shares of the medical research company’s stock valued at $483,000 after buying an additional 291 shares in the last quarter. Trinity Legacy Partners LLC increased its stake in Amgen by 1.6% during the 3rd quarter. Trinity Legacy Partners LLC now owns 15,382 shares of the medical research company’s stock worth $4,993,000 after buying an additional 239 shares in the last quarter. Tandem Investment Advisors Inc. raised its holdings in shares of Amgen by 107.4% during the third quarter. Tandem Investment Advisors Inc. now owns 1,655 shares of the medical research company’s stock valued at $534,000 after acquiring an additional 857 shares during the last quarter. Finally, Dudley Capital Management LLC purchased a new position in shares of Amgen in the third quarter valued at approximately $303,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on AMGN shares. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. TD Cowen upped their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price target (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $333.50.

Get Our Latest Analysis on Amgen

Amgen Stock Up 0.0 %

NASDAQ:AMGN opened at $321.91 on Friday. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock’s fifty day moving average is $323.96 and its two-hundred day moving average is $316.68. The stock has a market capitalization of $173.04 billion, a price-to-earnings ratio of 41.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. Amgen’s dividend payout ratio (DPR) is 115.24%.

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.